We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $102.65 · 22 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Farallon funds hold multi‑million share positions in BridgeBio (NASDAQ: BBIO) - Stock Titan
Farallon funds hold multi‑million share positions in BridgeBio (NASDAQ: BBIO) Stock Titan
BBIO Maintained by Morgan Stanley -- Price Target Raised to $98.00 - GuruFocus
BBIO Maintained by Morgan Stanley -- Price Target Raised to $98.00 GuruFocus
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $110 - Moomoo
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $110 Moomoo
FDA grants Priority Review to BridgeBio (NASDAQ: BBIO) BBP-418 NDA - Stock Titan
FDA grants Priority Review to BridgeBio (NASDAQ: BBIO) BBP-418 NDA Stock Titan
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 04. | After market close (AMC) | $-0.58 | — | — | $224.98M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-0.88 | — | — | $116.63M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-1.46 | — | — | $216.02M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-0.59 | — | — | $213.29M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 28. | Morgan Stanley | — | Maintain | Overweight → Overweight | — | Morgan Stanley: Overweight |
| 2026. 05. 28. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 05. 27. | Raymond James | — | Downgrade | Outperform → Market Perform | — | Raymond James: Outperform → Market Perform |
| 2026. 05. 19. | Citigroup | — | Initiate coverage | — → Neutral | — | Citigroup: Neutral |
| 2026. 05. 11. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 05. 08. | Evercore ISI Group | — | Maintain | Outperform → Outperform | — | Evercore ISI Group: Outperform |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 3,120,631 | $231.74B | 0.20% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 1,947,047 | $148.93B | 0.23% | — | New position |